<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156216">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01665092</url>
  </required_header>
  <id_info>
    <org_study_id>GM103799</org_study_id>
    <nct_id>NCT01665092</nct_id>
  </id_info>
  <brief_title>Rapid Administration of Carnitine in sEpsis</brief_title>
  <acronym>RACE</acronym>
  <official_title>Phase 2 Study of Levo-Carnitine for Vasopressor Dependent Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Mississippi Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of General Medical Sciences (NIGMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Mississippi Medical Center</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prior work has shown that exogenous L-carnitine administration enhances glucose and lactate
      oxidation, attenuates fatty acid toxicity, and improves endothelial-smooth muscle coupling
      and cardiac mechanical efficiency.  The overall goal of this proposal is to investigate
      L-carnitine as a novel adjunctive treatment of septic shock. In this study the investigators
      will test our primary hypothesis: Early adjunctive L-carnitine administration in vasopressor
      dependent septic shock will significantly reduce cumulative organ failure at 48 hours with
      an associated decrease in 28-day mortality suggesting the need for further phase III study.
      To accomplish this the investigators will conduct a phase II, double blinded, placebo
      controlled, adaptive randomized trial of 250 eligible patients with vasopressor-dependent
      septic shock. Study subjects will be assigned to one of four arms: low (6g), medium (12g) or
      high (18g) dose intravenous L-carnitine or placebo for 12 hours as a part of early
      resuscitative care.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>delta SOFA</measure>
    <time_frame>48 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>28 day</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carnitine Low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levo-Carnitine 6g</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carnitine Medium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levo-Carnitine 12 g</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carnitine High</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levo-Carnitine 18 g</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levo-Carnitine</intervention_name>
    <arm_group_label>Carnitine Low</arm_group_label>
    <arm_group_label>Carnitine Medium</arm_group_label>
    <arm_group_label>Carnitine High</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Suspected or confirmed infection (examples include but are not limited to: white
             cells in a normally sterile body fluid; perforated viscus; radiographic evidence of
             pneumonia in clinical symptoms; a syndrome associated with a high risk of infection
             e.g. cellulitis, cutaneous abscess, ascending cholangitis, toxic shock syndrome,
             fever of unknown origin with high suspicion of infectious etiology)

          2. Any two of four criteria of systemic inflammatory response as defined by the 2001
             ACCP/SCCM Consensus Conference Committee;

          3. Recognition of septic shock and initiation of quantitative resuscitation within 24
             hours of enrollment;

          4. Requirement of high dose vasopressors for ≥4 hours to treat shock: Norepinephrine &gt;
             0.05mcg/kg/min; dopamine &gt;10mcg/kg/min; Phenylephrine &gt;0.4 mcg/kg/min; epinephrine &gt;
             0.05 mcg/kg/min;

          5. Cumulative sequential organ failure assessment (SOFA) score of ≥ 6;

          6. Blood lactate level of &gt;2.0 mMol/L.

        Exclusion Criteria:

          1. Age &lt;18 years;

          2. Pregnancy or breastfeeding;

          3. Any primary diagnosis other than sepsis;

          4. Established Do Not Resuscitate status or advanced directives restricting aggressive
             care or treating physician deems aggressive care unsuitable;

          5. Any history of seizures or a known seizure disorder;

          6. Any known inborn error of metabolism;

          7. Anticipated requirement for surgery that would interfere with the 12 hour infusion
             time;

          8. Active participation in another interventional study;

          9. Cardiopulmonary resuscitation (chest compression or defibrillation) prior to
             enrollment;

         10. Known systemic allergy to L-carnitine.

         11. Severe immunocompromised state (e.g. subject has neutropenia [receiving cytotoxic
             chemotherapy with absolute neutrophil count &lt;500/uL or expected to decline to &lt; 500
             uL within the next three days).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan Jones, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Mississippi Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alan Jones, MD</last_name>
    <phone>601-984-5571</phone>
    <email>aejones@umc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Henry Wang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Henry Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univeristy of California Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Green, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Deb Diercks, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Jeffrey Green, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christiana Care Health Services</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ryan Aronold, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ryan Arnold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Courtney, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mark Courtney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Kline, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jeffrey Kline, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BIDMC</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathan Shapiro, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nathan Shapiro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rob Sherwin, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rob Sherwin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>29316</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan Jones, MD</last_name>
      <phone>601-984-5443</phone>
      <email>aejones@umc.edu</email>
    </contact>
    <investigator>
      <last_name>Alan Jones, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cooper University Hospital</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Trzeciak, MD</last_name>
    </contact>
    <investigator>
      <last_name>Stephen Trzeciak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mike Runyon, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mike Runyon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 26, 2014</lastchanged_date>
  <firstreceived_date>August 11, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Mississippi Medical Center</investigator_affiliation>
    <investigator_full_name>Alan Jones</investigator_full_name>
    <investigator_title>Professor of Emergency Medicine</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carnitine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
